Skip to main content

Advertisement

SpringerLink
Log in

Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

  • ORIGINAL ARTICLE
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

In India up to 50 % of breast cancer patients still present as locally advanced breast cancer (LABC). The conventional methods of metastatic work up include physical examination, bone scan, chest & abdominal imaging, and biochemical tests. It is likely that the conventional staging underestimates the extent of initial spread and there is a need for more sophisticated staging procedure. The PET/CT can detect extra-axillary and occult distant metastases and also aid in predicting response to chemotherapy at an early point in time. To evaluate the utility of FDG PET/CT in initial staging and response assessment of patients with LABC receiving NACT. A prospective study of all biopsy confirmed female patients diagnosed with LABC receiving NACT from April 2013 to May 2014. The conventional work up included serum chemistry, CECT chest and abdomen and bone scan. A baseline whole body PET/CT was done in all patients. A repeat staging evaluation and a whole body PET/CT was done after 2/3rd cycle of NACT in non-responders and after 3/4 cycles in clinical responders. The histopathology report of the operative specimen was used to document the pathological response. The FDG PET/CT reported distant metastases in 11 of 38 patients, where as conventional imaging revealed metastases in only 6. Almost all the distant lesions detected by conventional imaging were detected with PET/CT, which showed additional sites of metastasis in 3 patients. In 2 patients, PET/CT detected osteolytic bone metastasis which were not detected by bone scan. In 5 patients PET CT detected N3 disease which were missed on conventional imaging. A total of 14 patients had second PET/CT done to assess the response to NACT and 11 patients underwent surgery. Two patients had complete pathological response. Of these 1 patient had complete metabolic and morphologic response and other had complete metabolic and partial morphologic response on second PET/CT scan. The 18 FDG PET/CT can detect more number of metastasis as well as additional sites of metastasis compared to conventional methods. The response assessment resulted in change of treatment regimen in 14 % of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Agarwal G, Ramakant P (2008) Breast cancer care in India: the current scenario and the challenges for the future. Breast Care 3:21–27

    Article  PubMed  PubMed Central  Google Scholar 

  2. AJCC (American Joint Committee on Cancer) (2010) In: Edge SB, Byrd DR, Compton CC et al (eds) Cancer staging manual, 7th edn. Springer, New York, p 347

    Chapter  Google Scholar 

  3. Tham YL, Kramer R, Osborne CK (2010) Evaluation of patients for metastasis prior to primary therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 4th edn. Lippincott Williams & Wilkins, Philadelphia, p 483

    Google Scholar 

  4. Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N et al (2008) Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19:1249–1254

    Article  CAS  PubMed  Google Scholar 

  5. Al-Husaini H, Amir E, Fitzgerald B, Wright F, Dent R, Fralick J et al (2008) Prevalence of overt metastases in locally advanced breast cancer. Clin Oncol (R Coll Radiol) 20(5):340–344

    Article  CAS  Google Scholar 

  6. Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K et al (2001) Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28:351–358

    Article  CAS  PubMed  Google Scholar 

  7. Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E et al (2008) Effect of (18) F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 71:695–704

    Article  PubMed  Google Scholar 

  8. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G et al (2008) Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751

    Article  PubMed  Google Scholar 

  9. Van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, Van Geldere D et al (2004) 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 22:1253–1259

    Article  PubMed  Google Scholar 

  10. Von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, German Breast Group et al (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10:R30

    Article  Google Scholar 

  11. De Boer RH, Saini A, Johnston SR, O’Brien ME, Ellis PA, Verrill MW et al (2000) Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. Breast 9:149–155

    Article  PubMed  Google Scholar 

  12. Auclerc G, Borel C, Khayat D, Soubrane C (1992) Weil M [Primary chemotherapy in the treatment of breast cancer]. Ann Chir Plast Esthet 37:663–669

    CAS  PubMed  Google Scholar 

  13. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002) Pathobiology of preoperative chemotherapy: findings from the national surgical adjuvant breast and bowel (NSABP) protocol B-18. Cancer 95:681–695

    Article  PubMed  Google Scholar 

  14. Van der Hage JA, Van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol 19:4224–4237

    PubMed  Google Scholar 

  15. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan cancer institute. J Clin Oncol 16:93–100

    CAS  PubMed  Google Scholar 

  16. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578–2581

    CAS  PubMed  Google Scholar 

  17. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V 3.2014. National Comprehensive Cancer Network. Available at http://bit.ly/jOuSUf. Accessed October 2, 2014.

  18. Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C et al (2013) 18F FDG PET/CT in patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 54:5–11

    Article  PubMed  Google Scholar 

  19. Wolfgang A (2009) Weber. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46:963–995

    Google Scholar 

  20. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemotherapy using positron emission tomography-initial evaluation. J Clin Oncol 11:2101–2111

    CAS  PubMed  Google Scholar 

  21. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D et al (2000) Positron emission tomography using [(18) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689–1695

    CAS  PubMed  Google Scholar 

  22. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F et al (2000) Positron emission tomography using [(18) F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676–1688

    CAS  PubMed  Google Scholar 

  23. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366–5372

    Article  PubMed  Google Scholar 

  24. McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI et al (2007) Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102:75–84

    Article  CAS  PubMed  Google Scholar 

  25. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose. J Clin Oncol 27:535–541

    Article  PubMed  Google Scholar 

  26. Dunnwald LK, Gralow JR, Ellis GK (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449–4457

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Groheux D, Hindie E, Giacchetti S, Delord M, Hamy AS, Roquancourt AD et al (2012) Triple negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at high risk of early relapse. J Nucl Med 53:249–254

    Article  CAS  PubMed  Google Scholar 

  28. Skoura EV, Datseris IE (2007) PET imaging in breast cancer. Hosp Chronicles 2:12–18

    Google Scholar 

Download references

Conflict of Interest

None of the Authors have any conflict of interest

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Sri Venkateswara Institute of Medical Sciences, Tirupathi, 517501, India

    Narendra Hulikal & Sivanath Reddy Gajjala

  2. Department of Nuclear Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupathi, 517501, India

    Teck Chand Kalawat

  3. Department of Pathology, Sri Venkateswara Institute of Medical Sciences, Tirupathi, 517501, India

    Radhika Kottu

  4. Department of Radiology, Sri Venkateswara Institute of Medical Sciences, Tirupathi, 517501, India

    Lakshmi Amancharla Yadagiri

Authors
  1. Narendra Hulikal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sivanath Reddy Gajjala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teck Chand Kalawat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Radhika Kottu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lakshmi Amancharla Yadagiri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Narendra Hulikal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hulikal, N., Gajjala, S.R., Kalawat, T.C. et al. Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Indian J Surg Oncol 6, 330–336 (2015). https://doi.org/10.1007/s13193-015-0421-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-015-0421-0

Keywords

Search

Navigation